Clinical Trials Directory

Trials / Completed

CompletedNCT06533930

Evaluation of the Relationship Between Optic Nerve Diameter and Optic Nerve Sheath Diameter Measured by Transorbital Sonography With Clinical, Radiological, and Electrophysiological Parameters in Multiple Sclerosis Patients

Status
Completed
Phase
Study type
Observational
Enrollment
136 (actual)
Sponsor
Kutahya Health Sciences University · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The primary aim of this study is to evaluate the reliability of optic nerve diameter (OND) and optic nerve sheath diameter (ONSD) measurements made with transorbital sonography (TOS) and magnetic resonance imaging (MRI) in patient groups that may progress with subclinical optic atrophy over time, such as those with multiple sclerosis (MS). The secondary aims of this study are to compare the relationship of TOS with visual evoked potentials (VEP) and optical coherence tomography (OCT) parameters used in the assessment of the afferent visual pathway in MS and its clinical subtypes and to evaluate the potential of TOS as a diagnostic and monitoring tool for detecting optic nerve atrophy, subclinical axonal loss, and clinical disability in MS.

Detailed description

The study included 102 patients with MS-81 with relapsing-remitting MS (RRMS), 19 with secondary progressive MS (SPMS), and 2 with primary progressive MS (PPMS)-as well as 34 healthy controls, all selected according to the inclusion and exclusion criteria. Demographic data for all participants, and clinical characteristics of the MS patient group, were recorded. Expanded Disability Status Scale (EDSS) measurements were performed for the patients. Then, TOS, orbital MRI, VEP and OCT examinations were applied to the individuals in the patient group on the same day for each eye. Measurements recorded included OND and ONSD by TOS and MRI, P100 latency and amplitude by VEP, and peripapillary retinal nerve fiber layer (pRNFL) thickness by OCT. In the healthy control group, OND and ONSD were measured using only transorbital TOS to establish normal measurement ranges.

Conditions

Interventions

TypeNameDescription
OTHERTransorbital SonographyOND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
OTHEROrbita Magnetic Resonance ImagingOND and ONSD of participants in the MS patient group were measured by orbita MRI.
OTHERVisual Evoked PotentialsP100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
OTHEROptical Coherence TomographypRNFL thickness of participants in the MS patient group were measured by OCT.

Timeline

Start date
2023-10-01
Primary completion
2024-04-01
Completion
2024-04-01
First posted
2024-08-01
Last updated
2025-08-29

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06533930. Inclusion in this directory is not an endorsement.